Pathogenesis of HIV-associated heart disease

AIDS

Volumn 17, Issue SUPPL. 1, 2003, Pages

  Barbaro, Giuseppe ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

AIDS; Autoimmunity; Cardiomyopathy; Cardiovascular disease; Chemokines; Cytokines; Highly active antiretroviral therapy; HIV

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DOXORUBICIN; ERYTHROPOIETIN; FOSCARNET SODIUM; GANCICLOVIR; NUCLEOSIDE; PENTAMIDINE; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN DISEASE; CARDIOMYOPATHY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; ENDOTHELIUM INJURY; HEART DILATATION; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KAPOSI SARCOMA; LEUKOPENIA; LIPOATROPHY; LIPODYSTROPHY; METABOLIC DISORDER; NONHODGKIN LYMPHOMA; NONHUMAN; NUTRITIONAL DEFICIENCY; PANCREATITIS; PATHOGENESIS; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; TORSADE DES POINTES;

EID: 0038204638     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304001-00003     Document Type: Review

References (60)

1. Barbaro G. Cardiovascular manifestations of HIV infection. J R Soc Med 2001, 94:384-390.
2. Barbaro G, Di Lorenzo G, Soldini M, et al. The intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 1999, 100:633-639.
3. Lipshultz SE. Dilated cardiomyopathy in HIV-infected patients [editorial]. N Engl J Med 1998, 339:1153-1155.
4. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002, 106:1420-1425.
5. Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001, 1:115-124.
6. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G, and the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators. Cardiac involvement in the acquired immunodeficiency syndrome. A multicenter clinical-pathological study. AIDS Res Hum Retroviruses 1998, 14:1071-1077.
7. Barbaro G, Di Lorenzo G, Soldini M, et al. Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of TNF-α and iNOS. AIDS 2000, 14:827-838.
8. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000, 7:223-242.
9. Gisselbrecht M. Vasculitis during human acquired immunodeficiency virus infection. Pathol Biol (Paris) 1999, 47:245-247.
10. Johnson RM, Little JR, Storch GA. Kawasaki-like syndromes associated with human immonodeficiency virus infection. Clin Infect Dis 2001, 32:1628-1634.
11. Shingadia D, Das L, Klein-Gitelman M, Chadwick E. Takayasu's arteritis in a human immunodeficiency virus-infected adolescent. Clin Infect Dis 1999, 29:458-459.
12. Koppel K, Bratt G, Eriksson M, Sandstrom E. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS 2000, 11:451-455.
13. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
14. Henry K, Melrow H, Huebsch J, et al. Severe coronary heart disease with protease inhibitors [letter]. Lancet 1998, 351:1328.
15. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998, 351:1958.
16. Jutte A, Schwenk A, Franzen C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? [Letter]. AIDS 1999, 13:1796-1797.
17. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors [letter]. Ann Intern Med 1999, 131:548.
18. Varriale P, Mirzai-tehrane M, Sedighi A. Acute myocardial infarction associated with anabolic steroids in a young HIV-infected patient. Pharmacotherapy 1999, 19:881-884.
19. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000, 2:478-481.
20. Nair R, Robbs JV, Chetty R, Naidoo NG, Woolgar J. Occlusive arterial disease in HIV-infected patients: a preliminary report. Eur J Vasc Endovasc Surg 2000, 20:353-357.
21. Witz M, Lehmann J, Korzets Z. Acute brachial artery thrombosis as the initial manifestation of human immunodeficiency virus infection. Am J Hematol 2000, 64:137-139.
22. Hadigan C, Meigs JB, Rabe J, et al. Increased PAl-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939-943.
23. Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001, 15:15-24.
24. Herskowitz A, Willoughby SB, Baughman KL, Schulman SP, Bartlett JD. Cardiomyopathy associated with anti-retroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992, 116:311-313.
25. Domanski MJ, Sloas MM, Follman DA, et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. Pediatrics 1995, 127: 137-146.
26. Lewis W, Grupp IL, Grupp G, et al. Cardiac dysfunction in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000, 80:187-197.
27. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000, 43:151-170.
28. Lipshultz SE, Orav EJ, Sanders SP, Hale HR, McIntosh K, Colan SD. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med 1992, 327:1260-1265.
29. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 2000, 343: 759-766.
30. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351: 1881-1883.
31. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001, 15:329-334.
32. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidemia in HIV disease. Curr Opin Lipidol 2001, 12:313-319.
33. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
34. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000, 25:312-321.
35. Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000, 23:57-76.
36. Smith D. Clinical significance of treatment-induced lipid abnormalities and lypodystrophy. J HIV Ther 2001, 6:25-27.
37. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001, 6:9-20.
38. Sonnenblick EH, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991, 99:557-561.
39. Deyton L, Walker R, Kovacs J, et al. Reversible cardiac dysfunction associated with interferon alpha therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 1989, 321:1246-1249.
40. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy:evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 1978, 88:168-175.
41. Brown DL, Sather S, Cheitlin MD. Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient. Am Heart J 1993, 125:1439-1441.
42. Raine AE. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implication of erythropoietin therapy. Lancet 1988, 1:97-100.
43. Arsura EL, Ismail Y, Freeman S, Karunakav AR. Amphotericin B-induced dilated cardiomyopathy. Am J Med 1994, 97:560-562.
44. Cohen AJ, Weiser B, Afzal Q, Fuhrer J. Ventricular tachycardia in two patients with AIDS receiving ganciclovir (DHPG). AIDS 1990, 4:807-809.
45. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsade de pointes after administration of thrimethoprim-sulfamethoxazole. Am J Cardiol 1987, 59:376-377.
46. Kasten-Sportes C, Weinstein C. Molecular mechanisms of HIV cardiovascular disease. In Cardiology in AIDS. Edited by Lipshultz SE. New York: Chapman & Hall; 1998:265-282.
47. Hoffman M, Lipshultz SE, Miller TL. Malnutrition and cardiac abnormalities in the HIV-infected patients. In Nutritional Aspects of HIV Infection. Edited by Miller TL, Gorbach S. London: Arnold; 1999:33-39.
48. Pellicelli A, Barbaro G, Palmieri F, et al. Primary pulmonary hypertension in HIV disease: a systematic review. Angiology 2001, 52:31-41.
49. Seoane L, Shellito J, Welsh D, de Boisblanc BP. Pulmonary hypertension associated with HIV infection. South Med J 2001, 94:635-639.
50. Golpe R, Fernandez-Infante B, Fernandez-Rozas S. Primary pulmonary hypertension associated with human immunodeficiency virus infection. Postgrad Med J 1998, 74:400-404.
51. Pellicelli AM, Palmieri F, D'Ambrosio C, et al. Role of human immunodeficiency virus in primary pulmonary hypertension:case reports. Angiology 1998, 49:1005-1011.
52. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension. Mayo Clin Proc 1998, 73:37-44.
53. Estok L, Wallach F. Cardiac tamponade in a patient with AIDS: a review of pericardial disease in patients with HIV infection. Mt Sinai J Med 1998, 65:33-39.
54. Chen Y, Brennessel D, Walters J, Johnson M, Rosner F, Raza M. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 1999, 137:516-521.
55. Silva-Cardoso J, Moura B, Martins L, Mota-Miranda A, Rocha-Goncalves F, Lecour H. Pericardial involvement in human immunodeficiency virus infection. Chest 1999, 115:418-422.
56. Miller RF, Howling SJ, Reid AJ, Shaw PJ. Pleural effusions in patients with AIDS. Sex Transm Infect 2000, 76:122-125.
57. Sanna P, Bertoni F, Zucca E, et al. Cardiac involvement in HIV-related non Hodgkin lymphoma: a case report and short review of the literature. Ann Hematol 1998, 77:75-78.
58. Duong M, Dubois C, Buisson M, et al. Non-Hodgkin's lymphoma of the heart in patients infected with human immunodeficiency virus. Clin Cardiol 1997, 20:497-502.
59. Dal Maso L, Serraino D, Franceschi S. Epldemiology of HIV-associated malignancies. Cancer Treat Res 2001, 104:1-18.
60. Barbaro G, Fisher SD, Pellicelli AM, Lipshultz SE. The expanding role of the cardiologist in the care of HIV infected patients. Heart 2001, 86:365-367.